Oncotarget

Clinical Research Papers:

Effects of liraglutide on hemodynamic parameters in patients with heart failure

Jin Ying Zhang _, Xin Yun Wang and Xiang Wang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62693-62702. https://doi.org/10.18632/oncotarget.18570

Metrics: PDF 505 views  |   HTML 851 views  |   ?  


Abstract

Jin Ying Zhang1, Xin Yun Wang1 and Xiang Wang1

1Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong, China

Correspondence to:

Jin Ying Zhang, email: zjy181@126.com

Keywords: glucagon-like peptide-1, heart failure, hemodynamic, pulse indicator continuous cardiac output, left ventricular function

Received: October 19, 2016     Accepted: June 02, 2017     Published: June 19, 2017

ABSTRACT

Glucagon-like peptide-1 analogues improve left ventricular function in patients with acute myocardial infarction. This study aimed to evaluate the effects of liraglutide on hemodynamic parameters in patients with heart failure. A total of 78 patients with heart failure were enrolled in this study between August 2014 and November 2015. Of these, 52 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. Hemodynamic measurements were made using transpulmonary thermodilution and arterial pulse contour analysis. At 7 days, the difference in change of the primary endpoint of cardiac output between the liraglutide group and control group was +1.1 1/min (95% CI +0.1 to +2.2; P < 0.001). Stroke volume was significantly higher in the liraglutide group compared with the control group (difference: +14.6 ml; P < 0.001). The difference in an increase in the left ventricular contractile index after 7 days of treatment was +210.7 mmHg/s (liraglutide versus control, 95% CI−92.1 to +501.5; P < 0.001). Liraglutide causes favorable changes in markers of inflammation and oxidative stress. Glucagon-like peptide-1 may be associated with improvement in left ventricular function in patients with heart failure. These findings need to be confirmed by larger invasive trials.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18570